Titus Renil S, Bhatia Ansh, Porto Joao G, Daher Jean C, Raymo Adele, Meyreles Maggie, Khandekar Archan, Rathinam Aravindh, Katz Jonathan, Marcovich Robert, Shah Hemendra N
Houston Methodist Hospital Houston Texas USA.
Department of Interventional Radiology University of Miami Miller School of Medicine Miami Florida USA.
BJUI Compass. 2025 Jul 21;6(7):e70061. doi: 10.1002/bco2.70061. eCollection 2025 Jul.
To evaluate the safety and efficacy of Holmium Laser Enucleation of the Prostate (HoLEP) in managing patients with a history of organ-preserving treatments (OPT: Radiation Therapy - RT, High Intensity Focused Ultrasound - HIFU) for Organ-Confined Prostate Cancer (OC-PCa).
We reviewed men undergoing "en-bloc" HoLEP between July 2017 and December 2023 from our institutional database to identify those with a history of OPT for OC-PCa (study group). A 1:2 matched-pair analysis was performed comparing these patients with a control group of men undergoing HoLEP for benign prostatic hyperplasia (BPH) without prior OPT. Demographic, perioperative and postoperative voiding parameters up to 1 year, as well as complications, were compared between groups. Unpaired t-tests were used for parametric variables and Wilcoxon Rank tests for non-parametric variables. A p-value<0.05 was considered statistically significant.
Of 660 patients, 15 had prior OPT before HoLEP. The time between OPT and HoLEP ranged from 3-month to 12-year. Associated urethral stricture and/or extensive prostatic calcification were present in five patients. Demographic and preoperative parameters were similar between the groups. However, the study group patient had significantly less resected tissue and higher rate of urinary incontinence at 3-month. Two patients (13.3%) continued to experience incontinence at 1-year. There was no clinically significant difference in postoperative improvement in voiding parameters amongst both groups.
HoLEP in patients with history of OPT for treatment of OC-PCa is associated with a higher risk of transient urinary incontinence.
评估钬激光前列腺剜除术(HoLEP)治疗有器官保留治疗(OPT:放射治疗 - RT、高强度聚焦超声 - HIFU)史的局限性前列腺癌(OC-PCa)患者的安全性和有效性。
我们回顾了2017年7月至2023年12月期间在我们机构数据库中接受“整块”HoLEP手术的男性患者,以确定有OC-PCa的OPT史的患者(研究组)。进行1:2配对分析,将这些患者与未接受过OPT的良性前列腺增生(BPH)患者接受HoLEP手术的对照组进行比较。比较两组之间的人口统计学、围手术期和术后长达1年的排尿参数以及并发症。参数变量使用未配对t检验,非参数变量使用Wilcoxon秩和检验。p值<0.05被认为具有统计学意义。
660例患者中,15例在HoLEP手术前有过OPT。OPT与HoLEP之间的时间间隔为3个月至12年。5例患者存在相关尿道狭窄和/或广泛前列腺钙化。两组之间的人口统计学和术前参数相似。然而,研究组患者在3个月时切除的组织明显较少,尿失禁发生率较高。2例患者(13.3%)在1年时仍有尿失禁。两组术后排尿参数改善情况无临床显著差异。
有OC-PCa的OPT治疗史的患者进行HoLEP手术与短暂性尿失禁风险较高相关。